Key result
Heart failure remains a major cause of morbidity, mortality, and hospitalization in the US, with significant healthcare costs.
Persistent HF burden warrants sustained clinical vigilance; leaves open scalable strategies to curb costs and hospitalizations.
Despite important therapeutic improvements in pharmacological and device therapies, the prognosis for patients with advanced cardiovascular disease is poor, even with optimal pharmacological and device management. Heart failure continues to be a major cause of morbidity and mortality in the US. It is the leading medical cause of hospitalization and is expected to result in an estimated direct and indirect cost to the healthcare system in 2009 of $37.2 billion.1
No takes yet. Share an insight, caveat, or question.
Zsebo et al. (2009) conducted a review in Heart failure. SERCA2a Gene Transfer Therapy was evaluated. Heart failure remains a major cause of morbidity, mortality, and hospitalization in the US, with significant healthcare costs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: